- Home
- ICCM vs KPTI Comparison
ICCM vs KPTI Comparison
Compare ICCM & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- KPTI
- Stock Information
- Founded
- ICCM 2006
- KPTI 2008
- Country
- ICCM Israel
- KPTI United States
- Employees
- ICCM N/A
- KPTI N/A
- Industry
- ICCM
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- KPTI Health Care
- Exchange
- ICCM Nasdaq
- KPTI Nasdaq
- Market Cap
- ICCM 75.8M
- KPTI 81.1M
- IPO Year
- ICCM N/A
- KPTI 2013
- Fundamental
- Price
- ICCM $1.41
- KPTI $0.60
- Analyst Decision
- ICCM Strong Buy
- KPTI Strong Buy
- Analyst Count
- ICCM 2
- KPTI 4
- Target Price
- ICCM $2.70
- KPTI $5.00
- AVG Volume (30 Days)
- ICCM 379.2K
- KPTI 840.0K
- Earning Date
- ICCM 04-02-2025
- KPTI 02-19-2025
- Dividend Yield
- ICCM N/A
- KPTI N/A
- EPS Growth
- ICCM N/A
- KPTI N/A
- EPS
- ICCM N/A
- KPTI N/A
- Revenue
- ICCM $3,671,000.00
- KPTI $145,237,000.00
- Revenue This Year
- ICCM $10.03
- KPTI $4.47
- Revenue Next Year
- ICCM $62.68
- KPTI $7.35
- P/E Ratio
- ICCM N/A
- KPTI N/A
- Revenue Growth
- ICCM 26.02
- KPTI N/A
- 52 Week Low
- ICCM $0.48
- KPTI $0.53
- 52 Week High
- ICCM $1.66
- KPTI $1.70
- Technical
- Relative Strength Index (RSI)
- ICCM 60.09
- KPTI 41.56
- Support Level
- ICCM $1.22
- KPTI $0.53
- Resistance Level
- ICCM $1.66
- KPTI $0.64
- Average True Range (ATR)
- ICCM 0.09
- KPTI 0.05
- MACD
- ICCM 0.01
- KPTI -0.00
- Stochastic Oscillator
- ICCM 43.18
- KPTI 44.13
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.